Compare iShares MSCI United Kingdom (FTSE) (EWU) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs IDEXX Laboratories, Inc. — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.93, while IDEXX Laboratories, Inc. trades at $576.42 (market cap $43.94B). The key difference: iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| EWU | IDXX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.68 | $766.68 |
52-Week Low | $39.80 | $514.61 |
Market Cap | — | $43.94B |
Enterprise Value | — | $44.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU, the iShares MSCI United Kingdom ETF, trades at $46.88, up 1.23% on the day. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. The fund provides exposure to UK equities, which are influenced by rising oil prices and Middle East tensions, as highlighted in recent financial news. A dividend of $0.67 is scheduled for payment on June 18, 2026.
The outlook for EWU is cautiously optimistic, supported by technical strength and sector gains in energy. However, risks include geopolitical volatility and potential economic slowdowns in the UK. Investors should weigh the ETF's diversification benefits against exposure to regional uncertainties and currency fluctuations.
IDXX trades at $572.38, up 5.86% over 24 hours, with a neutral technical signal and strong fundamentals. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics and AI integration. Cash flow from operations remains healthy at $1.18 billion, though net cash flow was negative $108 million due to financing activities.
Outlook is positive given consistent earnings beats and analyst consensus leaning buy (59% of ratings). Key risks include high valuation multiples (P/E 40.99) and competitive pressures in medical devices. The stock's proximity to its 52-week high suggests momentum but warrants caution on pullbacks. Institutional sentiment is bolstered by product expansions like taeniid tapeworm detection and SDMA integration for kidney disease screening.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
